---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-24-000053"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2024-12-11T23:59:59+00:00"
generated_at: "2026-05-29T04:38:05.804956+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Altimmune reports pemvidutide Phase 1b MASLD data: LFC reduced up to 68.5%

## Summary
- Pemvidutide reduced liver fat content (LFC) by up to 68.5% from baseline over 12 weeks in 94 MASLD patients.
- Total cholesterol decreased by up to 12.2% and triglycerides by up to 44.6% after 12 weeks of treatment.
- Presented at AASLD The Liver Meeting from a 12-week Phase 1b trial in overweight/obese MASLD subjects.
- Subjects received once-weekly subcutaneous pemvidutide (1.2mg, 1.8mg, 2.4mg) or placebo.

## SEC filing metadata
- accession: 0001326190-24-000053
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2024-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619024000053/0001326190-24-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619024000053/alt-20241115x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-24-000053
- JSON: https://secwatch.observer/filing/0001326190-24-000053.json
- Plain text: https://secwatch.observer/filing/0001326190-24-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.